A scientific reference, not a shop.

AOD-9604 is a synthetic peptide based on the C-terminal fragment (residues 176-191) of human growth hormone, originally investigated in the research literature as a candidate anti-obesity compound. Most available evidence comes from preclinical in-vitro and animal studies examining lipid metabolism, and early-phase human studies reported in the literature did not establish meaningful efficacy for the originally proposed indication. It is discussed here strictly for research and educational reference; this profile makes no claims about safety, effectiveness, or suitability for any use. Terminology, sequence descriptions, and characterization vary between sources and require editorial and source verification.

BPC-157 (Body Protection Compound 157) is a synthetic pentadecapeptide whose sequence corresponds to a fragment described in studies of a protein found in human gastric juice. It appears in the research literature mainly through preclinical (animal and in vitro) work exploring tissue-repair and cytoprotective pathways, while well-controlled human clinical data remain very limited. BPC-157 is not an approved drug and is treated here strictly as a research compound. Reported findings should be interpreted cautiously given the early stage and design limitations of the available studies.

CJC-1295 is a synthetic peptide discussed in the research literature as a long-acting analog of growth hormone-releasing hormone (GHRH), derived from a modified GHRH(1-29) sequence. It is described as a reference compound for studying GHRH-receptor signaling and the growth hormone (GH) axis, with its characterization drawn largely from in vitro work and early pharmacology and animal models. Terminology varies between sources: "CJC-1295" may refer to a version carrying a Drug Affinity Complex (DAC) or a version without DAC, which differ in reported properties and warrant source verification. Available evidence is limited and requires careful interpretation due to study design and translation limitations.

CJC-1295 with DAC is a synthetic analog of growth hormone-releasing hormone (GHRH) discussed in the research literature as a laboratory compound. It pairs a modified GHRH(1-29) peptide sequence with a Drug Affinity Complex (DAC) moiety that sources describe as binding to circulating albumin, a property those sources report as extending the molecule's reported duration of action. It is examined in preclinical and mechanistic contexts as a tool for studying GHRH-receptor signaling and growth hormone release. The available evidence is limited and largely preclinical, terminology varies between sources, and any claims should be interpreted cautiously and verified editorially.

DSIP (delta sleep-inducing peptide) is a short, naturally occurring nonapeptide first described in the 1970s in early animal studies of sleep physiology, from which its name derives. It is discussed in the research literature largely in connection with sleep and circadian regulation, stress-hormone (HPA-axis) signaling, and related neuromodulatory processes, though its precise biological role and mechanism remain poorly defined. The available evidence is limited, much of it decades old and preclinical, and findings have been inconsistent across studies. This profile is an educational, research-use-only summary and is not a recommendation for any human or animal use.

Epitalon is a synthetic tetrapeptide (Ala-Glu-Asp-Gly, also written AEDG) developed as a short-peptide analog of Epithalamin, a preparation originally associated with the pineal gland, and is described in the research literature as a "peptide bioregulator." It is most often discussed in preclinical work relating to telomere biology, telomerase activity, and pineal/melatonin signaling, primarily in cell-culture and rodent models. Human data are limited and concentrated within a small number of research groups, so findings require careful interpretation due to study design and translation limitations. Terminology varies across sources (Epitalon, Epithalon, Epithalone), and it should not be conflated with the parent extract Epithalamin. This profile is educational and research-oriented and does not describe human or animal use.

GHK-Cu (copper tripeptide-1) is a naturally occurring copper-binding tripeptide that has been examined in laboratory and animal research as a copper-transport and tissue-signaling molecule. Most of the available literature is preclinical (in vitro and animal models), and findings should be interpreted cautiously given limited human-relevant data and well-known translation challenges. This profile is provided for research and educational purposes only and does not describe, recommend, or endorse any human or animal use. Terminology and formulations vary across sources and require independent editorial verification.

"GLOW" is not a single defined peptide but a term used by some vendors and online communities to describe a combination product, most often reported to contain the copper-peptide GHK-Cu alongside BPC-157 and TB-500 (a thymosin beta-4 fragment), peptides discussed in tissue-repair research contexts. Terminology varies between sources — closely related names such as "KLOW" are reportedly used for overlapping but different combinations — so the exact composition cannot be assumed and requires editorial and source verification. The individual constituents have been discussed in preclinical and in-vitro research, but the blend as a fixed combination has not, to our knowledge, been characterized in controlled studies. Evidence is limited and should be interpreted cautiously given study-design and translation limitations.

IGF-1 LR3 (Long R3 IGF-1) is a recombinant analog of insulin-like growth factor 1, modified so that it binds IGF-binding proteins (IGFBPs) less tightly than the native hormone. In the research literature it is described primarily as a cell-culture and bioprocess reagent and as a tool for studying IGF-1 receptor signaling, where it is reported to show greater in-vitro potency than native IGF-1. It is not an approved drug, and the available evidence is largely preclinical and mechanistic rather than clinical. Terminology and material identity vary between sources and should be verified editorially.

Ipamorelin is a synthetic pentapeptide categorized in the research literature as a growth hormone secretagogue and discussed primarily in preclinical and laboratory settings. It is described as an agonist of the ghrelin receptor (growth hormone secretagogue receptor, GHS-R1a) that has been reported to influence endogenous growth hormone release in animal and in-vitro models. The available evidence is limited and largely non-clinical, and findings should be interpreted cautiously given study-design and translation constraints. This profile is provided for research and educational reference only and is not a recommendation for any use.

KLOW is an informal, vendor-coined name for a multi-peptide blend rather than a single defined molecule, and its reported composition varies between sources. It is most often described in the research and supplier literature as combining KPV, the copper tripeptide GHK-Cu, BPC-157, and a thymosin beta-4 fragment (commonly labeled TB-500), though this should be confirmed against original source material. Because it is a blend, the available literature concerns the individual components — most of it preclinical (in-vitro and animal) — rather than "KLOW" as a tested entity. Any description of combined behavior is not established and requires careful, source-verified interpretation.

KPV is a synthetic tripeptide (lysine-proline-valine) that corresponds to the C-terminal fragment of alpha-melanocyte-stimulating hormone (α-MSH). It is discussed in the research literature primarily in the context of mechanisms reported as anti-inflammatory in in-vitro and animal models. Publicly available human clinical evidence is limited, and findings should be interpreted cautiously given the preclinical nature of most studies and known translation limitations. KPV is handled as a research-use-only compound and is not an approved therapy for any use.

LL-37 is the principal peptide derived from the human cathelicidin precursor protein hCAP-18, named for its two N-terminal leucine residues and length of 37 amino acids. In the research literature it is discussed mainly as a cationic host-defense and immunomodulatory peptide, with the large majority of published work conducted in vitro and in animal models. Activities described in that literature include interactions with microbial membranes and modulation of innate-immune signaling, but the evidence is largely preclinical and requires careful interpretation due to study-design and translation limitations. RUO Report covers LL-37 for documentation and research-context purposes only, and makes no claims regarding safety, efficacy, or use.

Melanotan II is a synthetic cyclic heptapeptide described in the research literature as a non-selective analog of alpha-melanocyte-stimulating hormone (α-MSH) that is characterized as an agonist at melanocortin receptors. It appears primarily in preclinical and mechanistic studies of melanocortin signaling. It is referenced here only as a research-use-only compound; it is not approved for human or veterinary use, and the available evidence is limited and requires careful interpretation due to study-design and translation limitations.

MOTS-c (mitochondrial open reading frame of the 12S rRNA type-c) is a mitochondrial-derived peptide that appears in the research literature primarily as a molecule discussed in the context of cellular metabolism and the stress response. The available evidence is largely preclinical, drawn from in vitro systems and animal models, with limited human data. This profile summarizes how MOTS-c is described in the scientific literature for research and documentation purposes only; it does not describe or imply any therapeutic use, benefit, safety, or outcome, and is not a recommendation for use in humans or animals. Findings should be interpreted cautiously given study-design and translation limitations.

PEG-MGF is a synthetic, polyethylene-glycol-modified form of a peptide derived from the C-terminal E-domain of mechano growth factor (MGF), itself a splice variant of insulin-like growth factor 1 (IGF-1, sometimes designated IGF-1Ec). It is discussed in the research literature as a laboratory compound examined primarily in preclinical and in-vitro contexts within muscle and tissue biology. PEGylation is described in the chemistry literature as a strategy reported to slow degradation and extend the apparent circulating half-life relative to the native peptide. Evidence specific to the pegylated form is limited, largely preclinical, and requires careful interpretation due to study design and translation limitations.

PT-141 is a common research designation for bremelanotide, a synthetic cyclic peptide in the melanocortin family that is structurally related to alpha-melanocyte-stimulating hormone (alpha-MSH) and associated with the melanotan analog lineage. In the research literature it is described as an agonist at melanocortin receptors, with particular interest in the centrally expressed MC3R and MC4R subtypes. Unlike many research peptides, bremelanotide has been examined in human clinical trials in addition to preclinical and mechanistic work, although the available findings should be interpreted conservatively in light of study design and preclinical-to-human translation limitations. This profile is an educational, research-use-only reference; it is not guidance for use in humans or animals and makes no claim regarding safety, efficacy, or any outcome.

Retatrutide (developer designation LY3437943) is an investigational synthetic peptide described in the research literature as a single molecule designed to act as an agonist at three receptors: the GLP-1, GIP, and glucagon receptors. It has been examined in preclinical (cell and animal) models and in early-to-mid-stage human clinical research concerning metabolic and energy-balance signaling pathways. It is not an approved product, and the available evidence is preliminary and should be interpreted cautiously given study-design and translation limitations. This profile is provided for research and educational purposes only and makes no claims regarding safety, efficacy, or any health outcome.

Selank is a synthetic heptapeptide analog of the naturally occurring immunomodulatory peptide tuftsin, discussed primarily in preclinical neuroscience and immunology research. In the literature it is examined mainly in rodent behavioral models and in mechanistic, cell-based systems rather than in humans. The available human evidence is limited and concentrated within a small number of research groups, so findings should be interpreted cautiously and not taken as established outcomes. It is described as a research compound and is not an approved therapeutic in major Western regulatory frameworks.

Semaglutide is a long-acting analogue of the incretin hormone GLP-1 (glucagon-like peptide-1) that is widely discussed in the research literature as an agonist of the GLP-1 receptor. Mechanistic and preclinical studies describe glucose-dependent modulation of insulin and glucagon signaling, gastrointestinal motility, and central appetite-related signaling pathways. Unlike most research peptides, semaglutide has also been the subject of extensive human clinical investigation in regulated medical settings; those data are distinct from research-use-only materials and do not establish any claim here. This profile is educational, neutral, and conservative, and all sourcing requires independent editorial verification.

Semax is a synthetic heptapeptide described in the research literature as an analog of a short fragment of adrenocorticotropic hormone (ACTH(4-10)), with the C-terminal Pro-Gly-Pro motif reported to slow enzymatic breakdown. It originated in Russian neuropharmacology research and has been examined mainly in preclinical (animal and in-vitro) models, alongside a limited and largely Russian-language clinical literature. It is discussed in the research literature as a neuropeptide that has been studied in relation to neurotrophic and neuromodulatory signaling, but the available evidence is limited and requires careful interpretation due to study design and translation constraints. This profile is research-use-only and makes no claim that Semax is safe, effective, or suitable for any human or animal use.

Sermorelin is a synthetic peptide corresponding to the first 29 amino acids of human growth hormone-releasing hormone (GHRH 1-29), described in the research literature as the biologically active fragment of GHRH. In research contexts it is discussed as a growth hormone secretagogue that is reported to act on pituitary GHRH receptors rather than supplying growth hormone directly. The available body of work spans dated/historical clinical pharmacology together with preclinical and in-vitro/mechanistic studies, and findings require careful interpretation due to study-design and translation limitations. This profile is educational and research-focused only and does not describe, recommend, or imply any use in humans or animals, nor any safety, effectiveness, or outcome.

TB-500 is a synthetic research peptide discussed in the literature in connection with thymosin beta-4 (TΒ4), a naturally occurring actin-binding peptide. It is most often described as corresponding to the actin-binding region of TΒ4, although sources vary on whether "TB-500" denotes the full-length protein or a shorter synthetic fragment, so its exact identity warrants editorial and source verification. The available data come predominantly from preclinical, animal, and in-vitro studies of thymosin beta-4 rather than from controlled human research, and the evidence is limited and requires careful interpretation due to study-design and translation limitations. TB-500 is handled as a research-use-only material and is not an approved therapeutic.

Tesamorelin is a synthetic, stabilized analog of growth hormone-releasing hormone (GHRH) that is characterized in the research literature as an agonist at the pituitary GHRH receptor. In the mechanisms described, it is reported to act on the somatotropic axis, influencing the release of endogenous growth hormone and downstream signaling involving insulin-like growth factor 1 (IGF-1). It has been examined in both clinical and preclinical settings, but the available evidence is limited and requires careful interpretation due to population-specific study designs and translation constraints. This profile is provided for research and educational purposes only; it is not a recommendation for any human or animal use and makes no claim of safety or efficacy.

Thymosin Alpha-1 (Tα1, also referred to in pharmaceutical contexts as thymalfasin) is a 28-amino-acid peptide derived from prothymosin alpha and originally characterized from thymic tissue. It is discussed in the research literature primarily as an immunomodulator, with reported effects on innate and adaptive immune signaling described mainly in vitro, in animal models, and in some clinical investigations conducted outside the United States. The evidence base is heterogeneous and should be interpreted cautiously given variation in study design, endpoints, and translational limitations. This profile is educational and for research-use context only; it is not a recommendation for human or animal use, and it makes no claim that the compound treats, prevents, or cures any condition.

Tirzepatide is a synthetic, single-chain peptide engineered as a dual agonist of the GIP and GLP-1 incretin receptors, sometimes referred to in the research literature as a "twincretin." It is discussed primarily in the context of incretin receptor signaling, glucose-dependent insulin secretion, and energy-balance pathways, and is associated with a comparatively large body of published literature relative to most research peptides. This profile is provided strictly for research and educational reference; it does not describe how the compound is used and makes no health, safety, or efficacy claims. Available evidence spans mechanistic, in-vitro, animal, and human pharmacology work and should be interpreted in light of study design and translational limitations.